PRESS RELEASE published on 03/04/2025 at 08:35, 1 year ago AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch AB Science's masitinib and its phase 3 principal investigator, neurologist Patrick Vermersch, featured in Life Sciences Magazine for potential breakthrough in Progressive MS Treatment AB Science Masitinib Patrick Vermersch Life Sciences Magazine Progressive MS Treatment
BRIEF published on 01/29/2025 at 19:08, 1 year 1 month ago AB Science Updates on Masitinib Platform Progress Multiple Sclerosis Masitinib Platform ALS Study Alzheimer’s Treatment AB Science Strategy
PRESS RELEASE published on 01/29/2025 at 19:03, 1 year 1 month ago AB Science today provides an update on its masitinib platform AB Science provides update on masitinib platform for ALS, MS, and AD. Positive results show potential for huge market sales. Debt negotiation planned Update AB Science Masitinib Platform Market Sales Debt Negotiation
BRIEF published on 01/24/2025 at 18:06, 1 year 1 month ago AB Science to Present Masitinib Update in Upcoming Webcast Pharmaceuticals Webcast Research Update AB Science Masitinib
PRESS RELEASE published on 01/24/2025 at 18:01, 1 year 1 month ago AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET AB Science to host live webcast on masitinib platform update on January 28, 2025, 5.30pm CET. Leading pharmaceutical company specializing in protein kinase inhibitors Pharmaceutical Company Live Webcast AB Science Protein Kinase Inhibitors Masitinib Platform
BRIEF published on 01/22/2025 at 19:04, 1 year 1 month ago AB Science Participates in Biomed Forum Investors Conference Investor Conference BIOMED Forum AB Science Masitinib Protein Kinase Inhibitors
PRESS RELEASE published on 01/22/2025 at 18:59, 1 year 1 month ago AB Science will participate in the Biomed Forum investors conference AB Science to participate in Biomed Forum Investors Conference organized by AllInvest Securities in Paris on February 4, 2025 Pharmaceutical Company BIOMED Forum AB Science Investors Conference AllInvest Securities
BRIEF published on 12/17/2024 at 19:09, 1 year 3 months ago AB Science presents the advances of AB8939 for acute myeloid leukemia Phase 1 AB8939 Acute Myeloid Leukemia Drug Resistance Potential Market
PRESS RELEASE published on 12/17/2024 at 19:04, 1 year 3 months ago AB Science provides a summary of the webcast held on December 16, 2024 AB Science provides an update on AB8939, a novel microtubule destabilizer and ALDH inhibitor in phase 1 for AML treatment. Potential market size exceeded EUR 2 billion per annum Market Potential AML Treatment AB Science Phase 1 AB8939
BRIEF published on 10/17/2024 at 19:33, 1 year 5 months ago AB Science Faces Setback in EMA Approval for ALS Treatment AB Science Masitinib Marketing Authorization ALS Treatment EMA Decision
Published on 03/17/2026 at 23:10, 26 minutes ago Redwood AI CEO Louis Dron Featured on Conversations That Matter to Discuss AI Chemistry Platform and Broader Applications
Published on 03/17/2026 at 22:30, 1 hour 6 minutes ago Galway Metals Appoints Red Cloud Financial Services to Provide Financial Advisory and Promotional Services
Published on 03/17/2026 at 21:30, 2 hours 6 minutes ago Rainy Mountain Announces Appointment of Colton Griffith to Board of Directors
Published on 03/17/2026 at 13:30, 10 hours 6 minutes ago Hillcrest Energy Technologies Confirms ZVS PCS1000 Prototype on Track for June 2026
Published on 03/17/2026 at 21:21, 2 hours 14 minutes ago KION GROUP AG successfully places a bond of € 500 million
Published on 03/17/2026 at 20:55, 2 hours 40 minutes ago EQS-Adhoc: thyssenkrupp nucera lowers its sales and EBIT outlook for the Group and the gH2 segment for FY 2025/26 due to higher project costs
Published on 03/17/2026 at 17:58, 5 hours 38 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/17/2026 at 07:00, 16 hours 36 minutes ago Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day 5 hours ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 day 5 hours ago Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 day 5 hours ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026
